Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab monotherapy in malignant pleural mesothelioma
jRCT2080223192Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in pleural mesothelioma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (central, modified criteria). Started May 2016; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080223192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223192.